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CONDENSATION 
 
The first-line use of LNG-IUS is less costly and more effective in comparison with COC or PROG 
for the treatment of DUB in Spain. 
 3 
ABSTRACT 
 
Objective: To compare the efficiency of the levonorgestrel-releasing intrauterine system (LNG-IUS) 
versus combined oral contraception (COC) and progestogens (PROG) in first-line treatment for 
dysfunctional uterine bleeding (DUB) in Spain. 
Study Design: A cost-effectiveness and cost-utility analysis of LNG-IUS, COC and PROG was 
carried out using a Markov model based on clinical data from literature and expert opinion. The 
population studied were women with a previous diagnosis of idiopathic heavy menstrual bleeding. 
The analysis was performed from the National Health System perspective, discounting both costs 
and future effects at the 3%. In addition, a sensitivity analysis (univariate and probabilistic) was 
conducted. 
Results: Results show that the greater efficacy of LNG-IUS translates into a gain of 1.92 and 3.89 
symptom-free months (SFM) after 6 months of treatment, respectively, versus COC and PROG 
(which represents an increase of 33% and 60% of the symptom-free time). Regarding costs, LNG-
IUS produces savings of 174.2-309.95 € and 230.54-577.61 € versus COC and PROG 
respectively, after 6 months-5 years. Apart from cost savings and gains in SFM, quality-adjusted 
life months (QALM) are also favourable to LNG-IUS in all scenarios, with a range of gains between 
1 and 2 QALM compared to COC and PROG. 
Conclusions: Results indicate that the first-line use of LNG-IUS is the dominant therapeutic option 
(less costly and more effective) in comparison with the first-line use of COC or PROG for the 
treatment of DUB in Spain. LNG-IUS as first line is also the option that provides greatest quality of 
life to patients. 
 
Key Words: Levonorgestrel-releasing intrauterine system; heavy menstrual bleeding; dysfunctional 
uterine bleeding; cost-effectiveness analysis; cost-utility analysis 
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INTRODUCTION 
 
Dysfunctional uterine bleeding (DUB), defined as heavy menstrual bleeding (HMB) for several 
consecutive cycles in woman of child-bearing age
1
, presents a high prevalence in western 
societies. In Spain, almost 20% of gynaecological visits are due to abnormal uterine bleeding
2
. 
 
Therapeutic alternatives for palliating DUB ranges from pharmacological treatments (hormonal and 
non-hormonal) to more aggressive surgical alternatives such as hysterectomy or endometrial 
ablation/resection. The levonorgestrel-releasing intrauterine system (LNG-IUS), marketed in Spain 
under the name of Mirena
®
 for the treatment of idiopathic DUB, is a depot progestogen (non-
surgical hormonal drug treatment) which guarantees a daily release of 20 µg of progestogen 
directly into the uterine cavity for at least five years
3
. Moreover, LNG-IUS is an alternative to the 
classic and surgical medical treatment for HMB and respects reproductive capacity
4
. In Spanish 
clinical practice, its greater effectiveness and high tolerability, have been demonstrated with regard 
to other non-surgical therapeutic alternatives
5-7
. Thus, the Spanish Society of Gynaecology and 
Obstetrics has recommended the use of LNG-IUS as first-line treatment for DUB, due to its multiple 
benefits
5
. However, it has not been evaluated the economic value of the treatment of DUB with 
LNG-IUS in Spain, yet. 
The primary endpoint of this study was to determine the economic value of treatment for idiopathic 
DUB with the LNG-IUS versus other medical options in women who initially wish to preserve 
reproductive function in Spain. 
 
 5 
MATERIALS AND METHODS 
 
Model 
 
A Markov Model of 6 months cycles was built to simulate resource use, symptom-free months 
(SFM), surgery-free months (SuFM) and quality of life (QoL) of a hypothetical cohort of women with 
idiopathic DUB treated with the most common therapy in Spain: (1) the levonorgestrel-releasing 
intrauterine system (LNG-IUS), (2) combined oral contraception (COC) and (3) progestogens 
(PROG) (figure 1). Tranexamic acid was excluded as a possible comparator as it is an acute 
treatment of the condition. The time horizon was established as 5 years, the LNG-IUS duration 
time, although, patients may continue with the same method by having a new device inserted after 
this period. 
 
The model allows to calculate the costs per patient associated with each option and to estimate the 
incremental cost-effectiveness of first-line treatment with LNG-IUS versus the alternatives, 
compared by means of the following formula: 
 
Costs LNG-IUS
 
– Costs compared alternative 
Effectiveness LNG-IUS – Effectiveness compared alternative 
 
In addition, a cost-utility analysis was carried out, in which the clinical results were measured in 
quality-adjusted life months (QALM). 
 
Due to the double indication of most of the treatments for DUB, four health states that combine the 
success/failure of the reduction of bleeding with success/failure in contraceptive control where 
defined. This allowed us to evaluate the specific results on bleeding reduction and those related to 
the interaction between both indications.  
 
The study was designed from the perspective of the National Health System (NHS) and health-care 
decision-makers, including only direct health-care costs. Both future costs and effects where 
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discounted at 3% as indicated by the Spanish guidelines
8
 and we inflated all costs to 2008 € using 
the consumer price index for all goods and services
9
. 
 
Parameters of the model 
 
The clinical and economic parameters of the model were extracted from the data published in the 
literature and validated by Spanish clinical experts (table 1). For progestogens, which are not a 
contraceptive treatment like the rest of the comparators, an 85% probability of contraception 
success was assumed, equivalent to the use of preservatives as the contraceptive method. On the 
other hand, a 100% efficacy and compliance for hysterectomy was assumed, thus rendering the 
possibility of treatment dropout impossible. 
 
The transition of patients reflected in the model when some treatment no longer controls the DUB, 
as well as the proportion of women who, following a pregnancy/abortion with one of the treatments, 
switch treatment, were obtained by expert opinion by means of a focus group battery (figures 2-3). 
Similarly, due to the experts' comments, it was included in the model that 80% of the total surgical 
procedures are hysterectomies and 20% resections. 
 
QALM constitutes an outcome measurement which includes the improvement in survival and gains 
in QoL. Utility values were obtained from data published according to the EuroQol-5D scale, where 
perfect health has a utility of 1, and the utility of death is 0. A utility of 0.95 was applied to DUB 
control, 0.55 to absence of DUB control, and 0.65 for patients undergoing surgery
16
. 
 
The use of health resources associated with each therapy was obtained from a group of Spanish 
clinical experts with experience in the management of these patients. Moreover, the 
pharmacological costs have been included in the model in Manufacturing Selling Price
17
 weighted 
by market share when needed. It must be mentioned that the cost of COC was assumed to be zero 
in our model, since it is a cost that has to be taken on by the patient and falls beyond the health 
system perspective. For the rest of the costs, the Spanish health-costs Database eSalud
18
 was 
used, which collects and updates Spanish costs from the literature and official tariffs from national 
 7 
and regional health services
19
. The LNG-IUS cost included the device cost (Mirena
®
, 112 €), the 
introduction visit and an additional insertion in 5% of the patients due to spontaneous device 
expulsion
20
 (table 2). 
 
Sensitivity analysis 
 
To evaluate the influence of the uncertainty of the parameters on results and to confirm the 
robustness of the outcomes obtained, a probabilistic sensitivity analysis was performed by means 
of a second-order Monte-Carlo simulation (1,000 times)
21
. For the sensitivity analysis, fixed 
distributions were selected (log-normal distribution for costs, normal distribution for resource use 
and beta distribution for probabilities) and the parameters of each distribution were estimated using 
the primary data collected
22
.  
 
Assumptions 
 
It was assumed that all patients started a new treatment when a previous therapy failed to control 
DUB, following an algorithm representing usual clinical practice in Spain (figure 2). With regard to 
contraceptive control, if any of the therapies failed, two possibilities were taken into account: 
patients aborted or completed pregnancy. The assumptions of the model were to consider that 
33% of the patients that get pregnant following contraceptive failure decide to abort (figure 3). In 
this case, they would not receive treatment for DUB again until 6-months after abortion. Sixty-
seven percent of the women that decide to complete the pregnancy were assumed not to treat 
DUB until 12 months after delivery/childbirth. 
 
 
 8 
RESULTS 
 
Health outcomes 
A review of the literature showed that control of DUB effectiveness after one year was achieved in 
75% of patients with the LNG-IUS (efficacy 82%), in 36% of the patients with COC (efficacy 46%) 
and in 2% of the PROG group (efficacy 57%). Effectiveness of all options is strongly influenced by 
compliance rates, that are especially low in oral treatments such as COC or PROG, being only 4% 
in the PROG due to the number of associated complications. Six-months model outcomes showed 
that higher effectiveness of LNG-IUS translated to 5.21 SFM, 3.29 for COC and 1.32 for PROG. 
Therefore, patients with COC have suitable control of DUB for only 55% of the time after 6 months, 
a value which is less for patients on treatment with PROG (22% of the time) in comparison with 
LNG-IUS (87%) (table 3). 
 
Patients starting treatment of DUB with LNG-IUS always presented a greater number of SFM for all 
time horizons (1st year 10.28 SFM and 5th year 50.53 SFM) and maintain DUB patients under 
control the 84-7% of the time (table 3).  
 
The lower effectiveness of the treatment with COC and PROG leads to a rapid change of 
treatment, so that, at the end of the first simulated year, LNG-IUS contribuited a 19% and a 22% to 
the SFM of therapeutic lines initiated with COC and PROG, respectively (figure 4). This transfer to 
other treatments that takes place mainly in the therapeutic lines that start with COC or PROG leads 
to an improvement in the effectiveness of these therapeutic lines with regard to the effectiveness of 
the initial method, resulting, for COC and PROG, respectively, in 7.52 SFM and 5.13SFM in the 
first year and 47.86 SFM and 45.59 SFM after five years, still not achieving the levels of the 
therapeutic line of LNG-IUS (table 3).  
 
Patient flow after five years showed that 20.7% patients were with LNG-IUS, 14.4% with resection, 
64.1% with hysterectomy and 0.8% with the others treatments, if the patients were initially assigned 
to therapeutic lines as follow: LNG-IUS (20%), COC (40%) or PROG (20%). 
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It should be mentioned that the greater effectiveness of LNG-IUS means that patients, besides 
benefiting from a less aggressive treatment, presented a mean number of SuFM after five years of 
34.79 months, while in patients in the therapeutic line starting with COC this figure was 30.31 
months, and for patients of the therapeutic line starting with PROG it was 28.05 months. Thus, 
therapeutic lines beginning treatment with COC or with PROG are referred to surgery before that 
starting with LNG-IUS. 
 
DUB considerably alters patients' daily activities, reflected in QoL (initially a reduction of 0.40 utility 
value respect to control state). In our study, QoL was greater for the therapeutic line starting with 
LNG-IUS than for the other alternatives (figure 5). The results indicated that QALM were 5.38 and 
50.89, respectively, after 6 months and 5 years for the therapeutic lines starting with LNG-IUS, 4.61 
and 49.82 with COC and 3.83 and 48.91 with PROG (table 3). 
 
We also evaluated the scenario considering only DUB control without taking into account 
contraception and we observed similar values of SFM, SuFM and QALM for all the compared 
options (table 3). 
 
Cost outcomes 
Mean costs per patient were 586.17 €, 760.40 € and 816.71 € after 6 months, respectively, for the 
therapeutic lines initiated with LNG-IUS, COC and PROG. Hence, the treatment line starting with 
COC was associated to an increase in health-care costs per patient with regard to the therapy 
initiated with LNG-IUS of 174 € after 6 months of treatment and 310 € after five years. Treatment 
initiated with PROG increased health costs between 230 and 578 €. So, even taking into account 
the zero cost of COC for the NHS, the initial cost of implanting the LNG-IUS is offset in only 6 
months. We can also see that the therapeutic line initiated with PROG always has the greater 
mean cost due to its limited rate of effectiveness (table 3). 
 
Cost-effectiveness analysis 
In view of the results obtained in the analysis for a 5-year time horizon, and including contraception 
control, the dominant therapeutic line was the one initiated with LNG-IUS, since it provided an 
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average cost per patient below the other therapies, providing with greater clinical benefits 
expressed as SFM, SuFM and QALM (figure 6). 
 
If only the effectiveness of the different therapies for the control of DUB is taken into account, 
disregarding the success of contraceptive control, once again the therapeutic line initiated with 
LNG-IUS is a cost-saving option respect to all comparators, providing also greater clinical benefits, 
whereby once again it is the dominant treatment line. Comparatively, mean costs of all treatment 
alternatives increase, despite the fact that the cost of pregnancy was not considered in this 
scenario, probably due to earlier transfer to surgery. 
 
Sensitivity analysis 
In the univariate sensitivity analysis performed for the variables of the model that were regarded as 
most relevant, in all scenarios and for all timeframes, therapeutic line initiated with LNG-IUS proved 
to be dominant or cost-effective. 
 
Robustness of results was tested considering the lowest efficacy value for LNG-IUS (74%) found 
by means of  the literature review, showing the same results. 
 
The results of the probabilistic analysis (1,000 different simulated patients) showed that taking into 
account the uncertainty in the main variables of the Markov Model, starting the treatment of DUB 
with LNG-IUS remains dominant versus the other alternatives. This indicates that even being a 
decision-maker’s willingness to pay for the increment in quality-adjusted life months almost 0 €, the 
treatment of choice should still be LNG-IUS. 
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COMMENTS 
 
The results of this study indicate that the option of initiating treatment for DUB with LNG-IUS, 
besides rendering it possible to preserve fertility, is associated to cost savings for the NHS as early 
as 6 months after treatment initiation and clearly provides a clinical and a QoL advantage for 
patients compared to using COC/PROG as first-line. Also, patient flow at five years from treatment 
initiation with LNG-IUS, COC or PROG shows that patients remain using LNG-IUS or have 
undergone surgery. 
 
It is important to remark that the cost-utility analysis performed took utility values published by a 
work by Sculpher
16
 which, on the date of this analysis, was the only work from which this type of 
figures could be obtained. The values of the study in question present important limitations. On the 
one hand, they were obtained using a technique known as Time Trade Off in a sample of 60 
women with complication-free DUB in the UK. The assigned value to the health state of the women 
with DUB was 0.55, a value which in principle seems very low, since according to this technique 
this value suggests that women would exchange almost 50% of their future life expectancy to avoid 
this health status. Moreover, they assigned a utility value of 0.95 for the non-DUB health status, 
which, taking into account that by convention the value of 1 is perfect health, indicates that the 
impact of the HMB in women of the sample was very significant. However, most of the international 
economic studies have used these utilities. 
 
To date, this is the first economic evaluation of LNG-IUS in the Spanish setting. The international 
literature contains some similar studies which compare the different surgical techniques
23-24
, and 
some included LNG-IUS
25-29
, although none of the studies may be directly comparable to this one. 
The only studies that have used a mathematical simulation model similar to the one built for the 
Spanish setting in this analysis are those by You et al., Clegg et al. and Blumenthal et al.
25,28-29
. 
 
In the study by You et al.
29
, which built a Markov Model and evaluated LNG-IUS, resection, 
hysterectomy and oral medication to a time frame of 5 years from the perspective of the NHS of 
Hong Kong. Results were expressed as cost-utility ratios, handling the same utility values we used 
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in our studies
16
. In that case, results were very similar to our owns, showing that treatment with 
LNG-IUS was dominant; however, they only took into account treatment effectiveness in the control 
of DUB without addressing the contraceptive issue. 
 
The study by Clegg et al.
28
 also built a Markov Model, and evaluated LNG-IUS, resection and 
hysterectomy over a timeframe of 5 years, from the perspective of the English National Health 
Service. The results of this analysis were in the same line as those obtained in our work, showing 
that patients beginning therapy with LNG-IUS presented lower costs and greater QALM than the 
other alternatives. 
 
On the other hand, the work by Blumenthal et al.
25
 is the closest to ours, since it is a Markov Model 
with a timeframe of 5 years, comparing combined oral contraception, LNG-IUS, resection and 
hysterectomy. Moreover, the patients' contraception intent is taken into account, and therefore 
included the possibility of contraceptive failure of the therapy in the analysis. The results were 
expressed as cost per success in DUB control and showed that treatment with LNG-IUS was the 
most cost-effective option. 
 
It is worth to remark that the assumptions made to palliate the limitations of our model were 
conservative. Despite all this, in all scenarios in which this therapy was addressed the initial cost of 
the implantation of LNG-IUS is offset thanks to its higher effectiveness in the control of DUB, 
making that only a small proportion of patients need to undergo surgery, which is ultimately more 
aggressive and costlier. 
 
In conclusion, the economic evaluation of beginning the treatment for DUB with LNG-IUS versus 
beginning with other options compared in this study indicates that LNG-IUS should be the non-
surgical treatment of choice for the control of dysfunctional uterine bleeding, as it is more effective 
and less costly for the health system in Spain. 
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Table 1. Rate of effectiveness after one year 
*It is assumed to be the same as for preservatives. 
Table 2: Unit costs 
*Cost of the device plus one visit and additional reinsertion in 5% of the patients 
Table 3: Results of the cost-effectiveness and cost-utility analysis 
 - 
Figure 1: Markov Model  
State SS: Success in the reduction of DUB and success in contraceptive control. 
Status SF: Success in the reduction of DUB and failure in contraceptive control.  
State FS: Failure in the reduction of DUB and success in contraceptive control. 
State FF: Failure in the reduction of DUB and failure in contraceptive control. 
COC= Combined oral contraception; PROG= Progestogens; LNG-IUS = Levonorgestrel-
releasing intrauterine system 
Figure 2: Treatment cascade in case of treatment failure in DUB control 
COC= Combination oral contraceptivon; PROG= Progestogens; LNG-IUS = 
Levonorgestrel-releasing intrauterine system 
* It is assumed that 20% of the patients undergo resection and 80% hysterectomy 
Figure 3: Failure in contraceptive control 
COC= Combination oral contraception; PROG= Progestogens; LNG-IUS = Levonorgestrel-
releasing intrauterine system 
Figure 4. Relative contribution of the therapeutic alternatives to effectiveness (SFM) 
COC= Combined oral contraception; PROG= Progestogens; LNG-IUD = Levonorgestrel-
releasing intrauterine system  
Figure 5: Increase in quality of life (%) of LNG-IUS versus the comparators in different time frames 
COC= Combined oral contraception; PROG= Progestogens  
Figure 6. Cost-effectiveness plane 
 - 
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Table 1. Rate of effectiveness after one year 
Therapy 
Dysfunctional Uterine 
Bleeding Control 
Contraceptive control References 
LNG-IUS 75%  99.9%  5 
Combination oral 
contraceptives 
36% 92% 10 
Progestogens 2% 85%* 11 
Resection 94% 100% 12-14 
Hysterectomy 100% 100% 15 
 
Table
  2 
Table 2: Unit costs 
Resource Unit cost (€, 2008) References 
LNG-IUS* 159.43 € 17-18 
Combination oral contraceptives 0 17 
Progestogens 12.72 17 
Resection 2,117 € 18 
Hysterectomy 4,234 € 18 
Gynaecology visit (First visit) 78.9 € 18 
Gynaecology visit (successive visits) 39.45 € 18 
Abortion 1140.41 € 18 
Partum 2,000 € 19 
  
  3 
Table 3: Results of the cost-effectiveness and cost-utility analysis 
 
  6 MONTHS 1 YEAR 5 YEARS 
  LNG-IUS COC PROG LNG-IUS COC PROG LNG-IUS COC PROG 
D
U
B
/C
o
n
tr
a
c
e
p
ti
o
n
 COST 586.17 € 760.37 € 816.71 € 987.64 € 1,323.41 € 1,529.98 € 3,099.37 € 3,409.32 € 3,676.98 € 
Difference - -174.20 € -230.54 € - -335.77 € -542.34 € - -309.95 € -577.61 € 
SFM 5.21 3.29 1.32 10.28 7.52 5.13 50.53 47.86 45.59 
Difference - 1.92 3.89 - 2.75 5.14 - 2.67 4.94 
Cost/ SFM gained - Dominant Dominant - Dominant Dominant - Dominant Dominant 
SuFM 6 6 6 11.25 10.81 10.78 34.79 30.31 28.05 
Difference - 0.00 0.00 - 0.43 0.47 - 4.47 6.74 
Cost/ SuFM gained - Dominant Dominant  Dominant Dominant - Dominant Dominant 
QALM 5.38 4.61 3.83 10.62 9.51 8.56 50.89 49.82 48.91 
Difference - 0.77 1.56 - 1.10 2.06 - 1.07 1.98 
Cost/ QALM gained - Dominant Dominant - Dominant Dominant - Dominant Dominant 
  6 MONTHS 1 YEAR 5 YEARS 
D
U
B
 
COST 625.81 € 799.82 € 841.97 € 1,027.10 € 1,347.91 € 1,526.98 € 3,137.33 € 3,328.93 € 3,545.09 € 
Difference - -174.01 € -216.16 € - -320.81 € -499.88 € - -191.60 € -407.76 € 
SFM 5.21 3.40 1.68 10.28 7.59 5.28 50.52 47.70 45.30 
Difference - 1.81 3.52 - 2.69 5.00 - 2.82 5.22 
Cost/ MLS gained - Dominant Dominant - Dominant Dominant - Dominant Dominant 
SuFM 6.00 6.00 6.00 11.25 10.81 10.78 34.65 29.93 27.04 
Difference - 0.00 0.00 - 0.43 0.47 - 4.72 7.61 
Cost/ SuFM gained - Dominant Dominant - Dominant Dominant - Dominant Dominant 
QALM 5.38 4.66 3.97 10.62 9.54 8.62 50.89 49.76 48.80 
Difference - 0.72 1.41 - 1.08 2.00 - 1.13 2.09 
Cost/ QALM gained - Dominant Dominant - Dominant Dominant - Dominant Dominant 
 
  1 
Figure 1: Markov Model  
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Figure 2: Treatment cascade in case of treatment failure in DUB control  
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Figure 3: Failure in contraceptive control  
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Figure 4. Relative contribution of the therapeutic alternatives to effectiveness (SFM)  
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Figure 5: Increase in quality of life (%) of LNG-IUS versus the comparators in different 
time frames  
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Figure 6. Cost-effectiveness plane  
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